Bupropion/mecamylamine - Cary Pharmaceuticals

Drug Profile

Bupropion/mecamylamine - Cary Pharmaceuticals

Alternative Names: INT-0003; INT-0003-2005; INT-0003/2005; INT-003-05; QuitPak; Smoking cessation therapy - Cary Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cary Pharmaceuticals
  • Class Norbornanes; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Smoking withdrawal

Highest Development Phases

  • No development reported Smoking withdrawal

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Smoking-withdrawal in USA (PO, Tablet)
  • 28 Feb 2014 Cary Pharmaceuticals seeking partner for phase III and commercial development of bupropion/mecamylamine for Smoking withdrawal. www.carypharma.com
  • 28 Feb 2014 Cary Pharmaceuticals completes a phase I safety and tolerability trial in Smoking withdrawal in USA before February 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top